Medical therapy following hospitalization for heart failure with reduced ejection fraction and association with discharge to long-term care: a cross-sectional analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population

Table 3 Age, race, and sex adjusted risk ratios for the associations between discharge to long-term care and medication use among REGARDS participants hospitalized for HFrEF

	Admission medication list^a	Discharge medication list^a	Claims within 1 year^b
Beta-blocker	1.1 (0.9, 1.4)	1.2 (1.0, 1.4)	1.0 (0.7, 1.4)
HFrEF beta-blocker^c	1.0 (0.6, 1.7)	1.3 (0.9, 1.9)	1.0 (0.6, 1.8)
ACEI/ARB	1.0 (0.6, 1.6)	1.0 (0.6, 1.6)	1.0 (0.6, 1.7)
Any diuretic	1.1 (0.8, 1.4)	1.0 (0.8, 1.2)	0.7 (0.4, 1.1)
Loop diuretic	1.2 (0.9, 1.6)	1.0 (0.8, 1.2)	0.7 (0.4, 1.1)
Aldosterone receptor antagonist	0.6 (0.1, 2.3)	0.7 (0.2, 2.2)	0.2 (0.0, 1.4)
Hydralazine in combination with isosorbide dinitrate	0.9 (0.2, 3.7)	0.2 (0.0, 1.3)	0.2 (0.0, 1.8)

HFrEF Heart failure with reduced ejection fraction, ACEI/ARB Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
^aDetermined from review of medical records
^bDetermined using Medicare claims data
^cCarvedilol, metoprolol succinate, or bisoprolol

ISSN: 1471-2261